التفاصيل البيبلوغرافية
| العنوان: |
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. |
| المؤلفون: |
Edara, Venkata Viswanadh, Norwood, Carson, Floyd, Katharine, Lai, Lilin, Davis-Gardner, Meredith E., Hudson, William H., Mantus, Grace, Nyhoff, Lindsay E., Adelman, Max W., Fineman, Rebecca, Patel, Shivan, Byram, Rebecca, Gomes, Dumingu Nipuni, Michael, Garett, Abdullahi, Hayatu, Beydoun, Nour, Panganiban, Bernadine, McNair, Nina, Hellmeister, Kieffer, Pitts, Jamila |
| المصدر: |
Cell Host & Microbe; Apr2021, Vol. 29 Issue 4, p516-516, 1p |
| مستخلص: |
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant. [Display omitted] • Antibodies from infected and vaccinated individuals bind to the B.1.351 RBD • Convalescent sera through eight months can neutralize the B.1.351 variant • Serum from vaccinated individuals retains neutralization against the B.1.351 variant In this study, Edara et al. (2021) report that, despite reduced antibody binding to the B.1.351 RBD, sera from infected (acute and convalescent) and Moderna (mRNA-1273)-vaccinated individuals were still able to neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective humoral immunity may be retained against this variant. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cell Host & Microbe is the property of Cell Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder